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The first diastereoselective synthesis of aryloxyphosphor-
amidate prodrugs of 3-deoxy-2,3-didehydrothymidine
monophosphate (d4TMP) was recently reported. The syn-
thetic approach utilized the chiral auxiliary (S)-4-isopropyl-
thiazolidine-2-thione (2). For this strategy, a stereochemically
pure phosphorodiamidate intermediate was needed. The
diastereoselective formation of this key compound was in-
vestigated by using different phenols and L-alanine methyl
or benzyl ester. Generally, the reaction with 3- or 4-substi-
tuted phenols led to significantly better diastereoselectivities
Introduction
Lipophilic nucleotide precursors (pronucleotides) are a
promising alternative to improve the biological activity of
nucleoside analogues in antiviral chemotherapy.[1] Pronu-
cleotides allow the intracellular delivery of 5-nucleotides
that need subsequent conversion to the 5-di- and 5-tri-
phosphates. The latter are ultimately the biologically active
compounds. Several pronucleotide strategies have been
reported, for example, the phosphoramidates,[2,3] the
cycloSal-phosphate triesters,[4] the mixed-S-acyl-2-thioethyl
compounds,[5] the HepDirect technique,[6] and recently the
bis(acyloxybenzyl) approach for the intracellular delivery of
nucleoside diphosphates.[7] These pronucleotide approaches
use different means of activation, for example, by enzymes
or chemical cleavage. In the first four cases, the compounds
are phosphoric acid derivatives that contain four different
residues attached to the phosphorus center. As a conse-
quence of the stereogenic center at the phosphorus atom,
diastereomers of the pronucleotides result because of the
additional chiral centers in the nucleoside analogs. In these
syntheses, pronucleotides are formed as mixtures of two
diastereomers, and in most cases, their separation has been
a difficult or impossible task. Importantly, in cases where
the diastereomers were separable, different biological ac-
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compared to their 2-substituted counterparts. Moreover, vari-
ation of the ester group in the amino acid residue resulted in
no significant differences with regard to the obtained dia-
stereoselectivity. From the reported results, a model for the
transition state was elaborated. Finally, eight new (SP)-aryl-
phosphoramidates were synthesized with very high dia-
stereoselectivities (up to  95% de) and tested for their anti-
HIV potency, showing a tendency for higher antiviral activity
from the (SP) diastereomers.
tivity, toxicity, and pharmacokinetic profiles were found for
the individual diastereomers.
Sofia et al. recently reported the discovery of phos-
phoramidate prodrugs of 2-deoxy-2-α-fluoro-2-β-C-
methyluridine-5-monophosphate that show strong inhibi-
tion of hepatitis C virus (HCV) replication.[8] The prodrugs
were prepared as a 1:1 mixture of diastereomers that were
separated by chromatography and crystallization. The anti-
viral evaluation of the individual diastereomers showed that
the (SP) diastereomer was  10-fold more active against
HCV than the (RP) diastereomer. Significant differences in
activity were also found for the phosphoramidates of 2-C-
methylcytidine. Again, the compounds were synthesized as
mixtures, and then the individual diastereomers were sepa-
rated by reversed-phase HPLC. The antiviral evaluation of
the diastereomers proved that the more lipophilic dia-
stereomer was about 8-fold more active against HCV than
the second diastereomer.[9] These examples clearly demon-
strate the importance of the phosphorus configuration on
the biological activity.
Consequently, the development of strategies for isomer-
ically pure nucleotide prodrugs is important. Recently, we
published the first diastereoselective synthesis of cycloSal-[10]
and (aryloxy)phosphoramidate prodrugs 1.[11] In both
cases, the routes led to diastereomerically almost pure pro-
drugs ( 95% de), and both pathways were based on the
use of chiral auxiliaries. Interestingly, one chiral auxiliary
was not suitable for the cycloSal-pronucleotides; instead,
the auxiliary had to be adapted to the target molecule. For
the diastereoselective synthesis of phosphoramidates 1, (S)-
4-isopropylthiazolidine-2-thione (2) was used as the chiral
auxiliary.[12] Scheme 1 summarizes the reaction sequence for
the synthesis of the nucleoside phosphoramidates 1 starting
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Scheme 1. Diastereoselective route to phosphoramidate prodrugs 1.
from auxiliary 2 and through achiral phosphorodichlorid-
ate 3, chiral phosphorochloridate 5, and phosphorodiamid-
ate 7.[11] The latter compound is the key intermediate of the
synthesis, because it is chiral and can be isolated.
The anti-HIV evaluation of the phosphoramidate pro-
drugs of nucleoside analog 3-deoxy-2,3-didehydro-
thymidine (d4T) confirmed the expected significant differ-
ences in the activities of the individually prepared dia-
stereomers (up to 65-fold).[11] In the recent report, only four
different phenols 4 and l-alanine methyl ester (6a) were
used in the reactions, and significantly different diastereo-
selectivities were obtained depending on the chosen phenol.
Here, a series of phenol derivatives (i.e., 4) were used to
gain more insight into this reaction. Moreover, in addition
to methyl ester 6a, the benzyl ester of l-alanine (6b) was
also used to expand the synthesis to other phenolic and
amino acid residues. Finally, the method was applied to the
syntheses of eight new phosphoramidate prodrugs starting
from diastereomerically pure phosphorodiamidate interme-
diates.
Results and Discussion
(S)-4-Isopropylthiazolidine-2-thione (2), prepared ac-
cording to the procedure of Delaunay et al.,[13] was treated
with an excess of phosphoryl chloride and NEt3 in CH2Cl2
to give phosphorodichloridate 3 (Scheme 1). The crude ma-
terial 3 displayed only one 31P NMR signal (δ = 3.70 ppm)
and thus was used directly in the next reaction. Previously,
Figure 1. Possible transition state for the preferential formation of (SP)-5.
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we reported that the conversion of 3 to the chiral phos-
phorochloridates 5 was performed using the three phenol
derivatives 4b,d,g as well as 1-naphthol (4l). As mentioned
above, the ratio of the two diastereomers obtained in this
step, where the chirality transfer took place, was clearly de-
pendent on the phenol derivatives and the reaction condi-
tions.[11]
The proposed transition state shown in Figure 1 should
lead to the preferential formation of the (SP) diastereomer
because of the interaction of the bulky isopropyl group with
the incoming phenolate nucleophile. A trigonal-bipyrami-
dal intermediate should form from the subsequent displace-
ment of the pro-(RP)-chloride anion. This proposed transi-
tion state is supported by the X-ray crystal structure of
thiophosphorodichloridate 8, which was previously ob-
tained.[14] Here, a series of 2- and 4-donor- or acceptor-
substituted phenols along with 3-substituted derivatives
(i.e., 4a–m) were studied (Figure 2). The results for the reac-
tion between phosphorodichloridate 3 and 4a–m to yield
phosphorochloridates 5 are given in Table 1.
First, the synthesis of the phosphorochloridates 5 was
carried out by cooling phosphorodichloridate 3 at –91 °C
in the presence of 0.7–1.0 equiv. of the phenols 4 and the
base DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) for 25–
75 min. The conversion of 3 ranged between a moderate
59% to an excellent 93% depending on the phenol used
(Table 1). The phosphorochloridates (RP/SP)-5 were ob-
tained in a ratio of up to 14:1. In all cases, the (SP)-config-
ured diastereomer was assumed to be preferentially formed
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Figure 2. Synthesis of phosphorodiamidate derivatives (RP)- or (SP)-11 and (RP)- or (SP)-12 through phosphorochloridates (RP)/(SP)-5.
Table 1. Conversion in the reactions leading to 5, 11, and 12, respectively, and the diastereomeric excess values for 5, 11, and 12.
5 Conversion of 3 [%][a] de [%][a] 11, 12[b] Conversion of 5 [%][a] de [%][a,c]
a 59 83 11a 39 74
b 64 51 11b 54 30
c 84 83 11c 66 81
d 93 81 11d 78 81
e 85 87 11e 64 85
f 74 86 11f 68 78
g 83 72 11g 60 72
h 81 28 11h 55 15
i 75 67 11i 46 25
j 66 75 11j 58 52
k 62 66 11k 36 44
l 79 36 11l 62 28
m 74 77 11m 59 72
12b 95 48
12d 93 81
[a] Conversion and de determined by 31P NMR spectroscopy of the crude mixture. [b] 11 (R6 = Me), 12 (R6 = Bn). [c] Starting materials
are the phosphorochloridate derivatives 5.
as a result of the addition/elimination mechanism. Always
the resonance signal of the (SP) diastereomer was found to
be low-field-shifted compared to that of the (RP) isomer
[e.g.: (SP)-5e, δ = –2.02 ppm; (RP)-5e, δ = –2.53 ppm; see
Exp. Sect.]. Due to their instability, phosphorochloridates 5
were purified only by one fast chromatography on a short
silica gel column and could not be separated into the indi-
vidual diastereomers. The diastereomeric ratio was found to
be strongly dependent on the substitution of the aromatic
moiety. Particularly, 2-methylphenol (4b) and 2-chloro-
phenol (4h) led to a significant reduction in diastereoselec-
tivity (51% de and 28% de, respectively). To our surprise,
2-methoxyphenol (4e) gave the best value (87% de) for all
the reactions. This unexpected difference may be attributed
to the different electronic and/or steric properties of the
chloro, methyl, and methoxy groups. Moreover, these ex-
periments also showed pronounced differences between the
diastereomeric ratios in the cases of 1- and 2-naphthol [4l
and 4m yielding 5l (36% de) and 5m (77% de), respectively].
Overall, the 2-substituted systems led to markedly lower
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diastereoselectivities. The use of substoichiometric amounts
was particularly necessary in the cases of phenols 4c,f,h–k.
If 1.0 equiv. of these phenols was used, considerable
amounts of diarylphosphoramidates 13 were observed as
side products. For the other phenols 4, compounds 13 were
formed in only very small amounts or not at all. The avoid-
ance of the formation of diarylphosphoramidates 13 was of
great importance, because compounds 13 and the phos-
phorochloridates 5 showed identical Rf values and conse-
quently could not be separated by column chromatography.
As a result, the diastereoselective synthesis of 5 worked best
by using the 3- and 4-substituted phenol derivatives. With
the exception of 2-methoxy, 2-substituted phenols led to
poor diastereoselectivities and thus are not suitable for this
diastereoselective synthesis. This loss of diastereoselectivity
could be related to the proposed transition state, although
a final explanation cannot be given (Figure 1).
Next, the syntheses of phosphorodiamidates (RP)- and
(SP)-11 and (RP)- and (SP)-12 (11, R6 = Me; 12, R6 = Bn)
were carried out by using the diastereomerically enriched
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mixtures of phosphorochloridates 5a–m and l-alanine
methyl or benzyl ester hydrochloride (9 and 10, respec-
tively). l-Alanine was previously identified as the most ef-
fective amino acid for use in this phosphoramidate ap-
proach, and the different esters in the amino acid moiety
also play an important role for the antiviral potency. The
reaction began by the addition of NEt3 at 0 °C, and then
the reaction mixture was stirred at room temperature for
16 h (Figure 2). The conversion of phosphorochloridates 5
and the diastereomeric excesses obtained for phosphorodi-
amidates 11 and 12 are also given in Table 1. In all cases,
the major diastereomer has the (RP) configuration, which
was supported earlier by three X-ray crystal structure
analyses.[11] In comparison to 5, the (RP) isomers of 11 or
12 displayed the low-field 31P NMR signal compared to
their (SP) counterparts [e.g.: (SP)-11d, δ = 1.43 ppm; (RP)-
11d, δ = –0.83 ppm; see Exp. Sect.].[11] Interestingly in all
cases, except for 11d and 12d, the diastereomeric excess val-
ues were found to be lower as compared to those of the
starting mixture of diastereomers 5 (Table 1) which points
to some isomerization during the second substitution of the
amino acid ester. In contrast to compounds 5, the phos-
phorodiamidates 11 and 12 were sufficiently stable to be
purified and separated to give the stereochemically pure
diastereomers by silica gel column chromatography ( 95%
de for each diastereomer).
Again, the substitution pattern in the aromatic residue
played a role with regard to the observed diastereoselectivi-
ties. Particularly, the 2-methylphenol phosphorodiamidate
derivative of the l-alanine methyl ester 11b was obtained in
a drastically lower diastereoselectivity compared to phos-
phorochloridate 5b. A reason for the loss in stereospecificity
may be related to the presence of diarylphosphoramidate
13. In all reactions of phosphorochloridates 5 leading to the
phosphorodiamidates 11, some amounts of 13 were ad-
ditionally formed. This was clearly proven by 31P and 1H
NMR spectroscopy and mass spectrometry. However, no
traces of the phenols were detected in the 1H NMR spectro-
scopic data of 5. It was reported previously that phos-
phoramidates 13 can also undergo substitution reactions
(Figure 3, pathway b).[15] In contrast to compounds 5, di-
aryl derivative 13 is an achiral compound with two identical
phenol groups. Thus, a reaction of 13 with the amino acid
ester should lead to a diastereomeric mixture of the target
compounds 11, which consequently lowers the overall dia-
stereospecificity of this reaction. In addition, it is still un-
known to what extent the leaving group differentiation be-
Figure 4. Excluded reaction to the formation of phosphorodiamidates 11d.
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tween the chloride and the phenolate moieties in starting
material 5 can be achieved. Assuming that a small fraction
of the reaction of 5 with the amino acid esters 9 and 10
took place with displacement of the phenolate, one should
expect intermediate 14 as a product (Figure 3, pathway c).
This material should be formed with inversion of configura-
tion at the P atom. In a subsequent step, the released phe-
nolate can then react with compound 14 with displacement
of the chloride anion and again with inversion of configura-
tion. In total, this scenario would lead to the products 11
with the inverted configuration (Figure 3, pathway a). How-
ever, the released phenolate could react with the starting
material 5 to lead to the diaryl derivative 13, again. There-
fore, both proposed reactions would lead to a reduction in
the stereochemical purity of the obtained phosphorodi-
amidates 11.
Figure 3. Proposed formation of side products 13 and 14 in the
synthesis of phosphorodiamidates 11.
To prove whether diarylphosphoramidates like 13 react
with the amino acid ester, a separate experiment was carried
out (Figure 4). However, by using an identical experimental
setup, no formation of the expected phosphorodiamidates
(RP)-11d or (SP)-11d was detected. The 31P NMR spectrum
of the crude reaction mixture showed no conversion at all.
Thus, this experiment excludes that the loss of stereoselecti-
vity is related to the formation of compound 13. Intermedi-
ate 14 still may play a role in the decrease of stereoselecti-
vity (Figure 3); however, the synthesis and isolation of inter-
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Figure 5. Synthesis of d4T-phosphoramidates 16j,k and 17b,d.
mediate 14 was unsuccessful. Thus, it is impossible to give
a final proof of the reaction mechanism explaining the for-
mation of the minor diastereomer (SP)-11.
Nevertheless, the formation of intermediate 14 can be
proven indirectly by the preparation of diaryl derivative 13.
If 14 is formed, 1 equiv. of phenol would be released, which
then could react in a subsequent reaction to give achiral
compounds 13 as well as the diastereomer of 11. Interest-
ingly, the use of l-alanine benzyl ester hydrochloride 10,
which was prepared according to the procedure of Joullié
et al.,[16] did not lead to the formation of diaryl derivative
13. Its use led to very high conversions and almost to the
same diastereomeric excess values as those of 5b,d (12b,
48% de; 12d, 81% de).
For the following reaction, phosphorodiamidates 11j,k
and 12b,d were separately treated with 3-deoxy-2,3-dide-
hydrothymidine (d4T, 15) to give phosphoramidate pro-
drugs 16j,k and 17b,d (Figure 5). The reactions were carried
out in a mixture of THF/CH3CN (1:1) with the addition
of tert-butylmagnesium chloride. The Grignard reagent was
used as a base analogous to Uchiyama’s method.[17]
Table 2 shows the isolated yields and diastereomeric pu-
rities of phosphoramidate prodrugs 16j,k and 17b,d. The
(SP) configuration at the phosphorus atom is supported by
comparison with the X-ray crystal structure of phos-
phoramidate prodrug (SP)-PSI-7977.[8] Furthermore, this
X-ray analysis supports our previously proposed reaction
mechanism for this base-induced substitution as being an
addition/elimination reaction occurring at the phosphorus
atom and proceeding with inversion of configuration, for
example, (RP)-11 to (SP)-16 and (RP)-12 to (SP)-17.[12] The
diastereomeric excess values were determined by 31P NMR
Table 3. Antiviral activity of phosphoramidates 16j, k and 17b, d.
EC50 [μm][a] CC50 [μm][b]
CEM/0[c] CEM/TK–[d] CEM/0
HIV-1(IIIB) HIV-2(ROD) HIV-2(ROD)
(SP)-16j 0.0210.0085 0.0300.014 0.0350.0078 542.8
(RP)-16j 0.130.071 0.180.028 0.180.099 19018
(SP)-16k 0.0420.030 0.0740.0035 0.0310.013 604.2
(RP)-16k 0.140.078 0.170.064 0.140.085 1442.1
(SP)-17b 0.450.12 0.580.0071 0.450.0 1018.5
(RP)-17b 0.190.035 0.400.0 0.270.0 9811
(SP)-17d 0.0290.024 0.0730.0078 0.0470.028 714.9
(RP)-17d 0.110.035 0.110.035 0.130.071 1159.2
d4T (15) 0.510.31 0.890.11 14016  250
[a] Antiviral activity in T-lymphocytes, 50% effective concentration. [b] Cytostatic activity, 50% cytostatic concentration. [c] Wild-type
CEM/0 cells. [d] Thymidine kinase deficient CEM TK– cells.
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after column chromatography and were found to be at least
85% de. Except for the 85% de value for phosphoramidate
prodrug (RP)-17b, the diastereomeric values almost corre-
sponded to the  95% de in the starting materials.
Table 2. Yields and diastereomeric excess values of phosphoramid-
ate prodrugs 16j,k and 17b,d.
(SP) δ(31P) Yield[a] de[b] (RP) δ(31P) Yield[a] de[b]
[ppm] [%] [%] [ppm] [%] [%]
16j 3.13 20 95 16j 2.62 26  95
16k 3.13 15 93 16k 2.56 50  95
17b 2.98 11  95 17b 2.59 28 85
17d 3.27 14 94 17d 2.62 44  95
[a] Isolated yields. [b] de determined by 31P NMR spectroscopy af-
ter purification.
Antiviral Evaluation
Phosphoramidates 16j,k and 17b,d were evaluated for
their anti-HIV activity in vitro. All compounds showed ac-
tivity against HIV-1 and HIV-2 in wild-type CEM/0 cell
cultures at a concentration range that was often superior to
that of the parental d4T (Table 3).
Moreover, it was interesting to observe that both dia-
stereomeric prodrugs of d4T kept full antiviral activity
against HIV-2 in TK-deficient CEM/TK– cells. In general,
the 4-substituted (SP) diastereomers 16j,k, and 17d were
found to be more active than the (RP) diastereomers (5-fold
in the case of 16j,k and 3-fold for 17d against HIV-2 in
CEM/TK-deficient cells). However, in the case of 2-methyl-
substituted phosphoramidate prodrugs 17b, the dia-
stereomers showed almost identical antiviral values.
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Conclusions
The diastereospecific synthesis of phosphoramidate pro-
drugs 16j,k and 17b,d was achieved by starting from stereo-
chemically pure phosphorodiamidates 11 and 12. These key
compounds were synthesized diastereoselectively in three
steps by using the chiral auxiliary (S)-4-isopropylthiazolid-
ine-2-thione (2). The formation of this key compound was
studied by investigating its dependence on different phenol
derivatives 4a–m and the l-alanine methyl or benzyl ester
hydrochloride (9 and 10, respectively) attached to the phos-
phorodiamidate moiety. The variation of the phenolic resi-
dues led to the proposed transition state shown in Figure 1,
explaining the preferential formation of (SP)-configured
phosphorochloridate derivatives 5. In addition, it was ob-
served that 3- and 4-substituted phenol derivatives led to
significantly better diastereoselectivities compared to 2-sub-
stituted phenols, which gave mostly poor stereoselectivities.
The variation of the amino acid ester residues did not lead
to significant differences with regard to the diastereoselec-
tivity. Finally, eight new (SP)-arylphosphoramidates were
synthesized as diastereomerically pure compounds and
tested for their antiviral activity. Interestingly, the (SP)-4-
substituted phosphoramidates were found to be antivirally
markedly more active than their (RP) counterparts, inde-
pendent of the substituent, demonstrating again the impor-
tance of diastereoselective access to these compounds. In
contrast, the 2-methyl derivatives were equipotent for un-
known reasons. Work to study the properties of the individ-
ual diastereomers is currently ongoing in our laboratories.
Experimental Section
General: All experiments were conducted under scrupulously dry
conditions and under nitrogen. The solvents CH2Cl2, CH3CN, and
NEt3 were distilled from CaH2 and stored over molecular sieves.
Et2O and THF (tetrahydrofuran) were distilled from sodium or
potassium benzophenone and stored over molecular sieves. Ace-
tone was distilled from phosphorus pentoxide and stored over mo-
lecular sieves. DBU was distilled under nitrogen and stored over
molecular sieves. The petroleum ether (boiling range 50–70 °C),
EtOAc, CH2Cl2, and CH3OH employed in chromatography were
distilled before use. For column chromatography, silica gel 60 (230–
400 mesh) was used. Thin layer chromatography was performed on
precoated aluminium plates 60 F254 with a 0.2 mm layer of silica
gel containing a fluorescence indicator. The NMR spectroscopic
data were recorded with 400 or 500 MHz spectrometers (AMX 400
or DRX 500). All 1H and 13C NMR chemical shifts are quoted in
ppm and were calibrated by solvent signals. 31P NMR chemical
shifts are quoted in ppm by using H3PO4 as an external reference.
High-resolution mass spectra were obtained with a VG Analytical
VG/70-250F spectrometer (FAB, m-nitrobenzyl alcohol matrix).
HR-ESI spectra were obtained with an Agilent Technologies ESI-
TOF 6224 spectrometer. Analytical HPLC was carried out with a
VWR-Hitachi LaChromElite HPLC system consisting of a VWR-
Hitachi 2130 Pump, autosampler, and VWR-Hitachi UV detector
2455. The column used was a Nucleodur C18 Isis, 5 μm (Mach-
erey–Nagel). Elution was performed by using a water/acetonitrile
(Sigma–Aldrich, HPLC grade) eluent: 0–80% CH3CN (0–60 min),
80–0% CH3CN (60–65 min), 0% CH3CN (65–70 min), a flow rate
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of 0.5 mL/min, and UV detection at 265 nm. The purity of phos-
phoramidate prodrugs 16 and 17 was checked by using HPLC, and
in all cases was  95%.
Preparation of [(4S)-4-Isopropyl-2-thioxo-1,3-thiazolidin-3-yl]phos-
phonic Dichloride (3): A solution of (4S)-4-isopropyl-1,3-thiazolid-
ine-2-thione (2, 0.80 g, 4.96 mmol) and phosphoryl chloride
(1.39 mL, 14.8 mmol) in CH2Cl2 (12 mL) was cooled to 0 °C. NEt3
(0.76 mL, 5.45 mmol) in CH2Cl2 (12 mL) was added dropwise. Fol-
lowing the addition, the reaction mixture was warmed to room
temperature and stirred for 16 h. The solvent was removed under
reduced pressure by using a high-vacuum pump, and the residue
was suspended in CH2Cl2 (1 mL) and Et2O (15 mL). The precipi-
tated triethylammonium chloride was filtered under nitrogen and
washed with Et2O (5 mL). The solvent of the filtrate was removed
under reduced pressure by using a high-vacuum pump to give the
crude product 3 as an oil. Further purification was not possible
due to high reactivity, and the 31P NMR spectrum showed only
one signal at δ = 3.70 ppm.
General Procedure A. Preparation of Aryl [(4S)-4-Isopropyl-2-thi-
oxo-1,3-thiazolidin-3-yl]phosphonochloridates 5: A solution of 3
(1.0 equiv.) and the phenol or 1-naphthol derivative 4 (0.7 or
1.0 equiv.) in acetone was cooled to –91 °C. DBU (1.0 equiv.) was
added dropwise to the vigorously stirred solution. After 25–75 min
(dependent on 4) at –91 °C, the reaction was quenched – without
allowing it to warm to room temperature – with saturated ammo-
nium chloride solution (approximately 10 mL) and extracted with
CH2Cl2 (3). The combined organic layers were dried with magne-
sium sulfate and concentrated under reduced pressure by using a
high-vacuum pump. The resulting residue was purified immediately
by very quick column chromatography (1.5 cm diameter, 54.5 cm
length) on silica gel (approximately 23 g) using petroleum ether
(boiling range 50–70 °C)/EtOAc (2:1). The solvent was removed un-
der reduced pressure by using a high-vacuum pump. Further purifi-
cation of 5 was not possible due to the decomposition of the chiral
auxiliary 2.
General Procedure B. Preparation of Alanine Derivatives 11 and 12:
A suspension of 5 (1.0 equiv.) and l-alanine methyl ester hydro-
chloride (9, 1.0 equiv.) or l-alanine benzyl ester hydrochloride (10,
1.0 equiv.) in CH2Cl2 was cooled to 0 °C. NEt3 (3.0 equiv.) was
added dropwise. Following the addition, the reaction mixture was
warmed to room temperature and stirred for 16 h. The reaction
was quenched with a saturated ammonium chloride solution and
the mixture extracted with CH2Cl2 (3). The combined organic
layers were dried with magnesium sulfate and concentrated under
reduced pressure by using a rotary evaporator. The resulting resi-
due was purified by column chromatography on silica gel [petro-
leum ether (boiling range 50–70 °C)/EtOAc, 2:1].
General Procedure C. Preparation of Thymidine Derivatives 16 and
17: A solution of d4T (15, 1.5 equiv.) in THF/CH3CN (1:1) was
cooled to 0 °C. tert-Butylmagnesium chloride (1.7 m solution in
THF, 3.0 equiv.) was added dropwise. Following the addition, the
reaction mixture was warmed to room temperature and stirred for
30 min. A solution of 11 or 12 (1 equiv.) in THF/CH3CN (1:1) was
added to the nucleoside suspension at 0 °C. Following the addition,
the reaction mixture was warmed to room temperature and stirred
for 5 d. The reaction was quenched with saturated ammonium
chloride solution and the mixture extracted with CH2Cl2 (3). The
combined organic layers were dried with magnesium sulfate and
concentrated under reduced pressure by using a rotary evaporator.
The resulting residue was purified by column chromatography on
silica gel (CH2Cl2/CH3OH, 39:1). The product was freeze-dried.
Diastereoselective Synthesis of (Aryloxy)phosphoramidate Prodrugs
5a: According to General Procedure A, compound 3 (1.38 g,
4.96 mmol) and phenol (4a, 0.47 g, 4.96 mmol) were dissolved in
acetone (9.2 mL). After the addition of DBU (0.75 mL,
4.96 mmol), the reaction mixture was stirred at –91 °C for 40 min.
Product 5a was obtained as a yellow oil (1.57 g, 94%). 1H NMR
(400 MHz, CDCl3): δ = 7.44–7.35 (m, 2 H, Ar), 7.34–7.27 (m, 3 H,
Ar), 5.03–4.93 (m, 1 H, 4-H), 3.66 (dd, 2JH,H = 11.6 Hz, 3JH,H =
8.5 Hz, 1 H, 5-H), 3.18–3.11 (m, 1 H, 5-H), 2.58–2.43 (m, 1 H, 6-
H), 1.13 (d, 3JH,H = 7.0 Hz, 3 H, 7-H or 8-H), 1.09 (d, 3JH,H =
7.0 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ =
–1.73, –1.61 (dr = 1:9.6; 81% de) ppm.
5c: According to General Procedure A, compound 3 (1.03 g,
3.72 mmol) and 3-methylphenol (4c, 0.27 mL, 2.60 mmol) were dis-
solved in acetone (6.9 mL). After the addition of DBU (0.39 mL,
2.60 mmol), the reaction mixture was stirred at –91 °C for 75 min.
Product 5c was obtained as a yellow oil (1.08 g, 83%). 1H NMR
(400 MHz, CDCl3): δ = 7.25–7.20 (m, 2 H, Ar), 7.11–7.02 (m, 2 H,
Ar), 4.99–4.93 (m, 1 H, 4-H), 3.62 (dd, 2JH,H = 11.5 Hz, 3JH,H =
8.5 Hz, 1 H, 5-H), 3.15–3.10 (m, 1 H, 5-H), 2.54–2.43 (m, 1 H, 6-
H), 2.33 (s, 3 H, Ph-Me), 1.09 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-
H), 1.06 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR
(162 MHz, CDCl3): δ = –1.71, –1.84 (dr = 12:1; 85% de) ppm.
5e: According to General Procedure A, compound 3 (1.03 g,
3.72 mmol) and 2-methoxyphenol (4e, 0.41 mL, 3.72 mmol) were
dissolved in acetone (6.9 mL). After the addition of DBU (0.56 mL,
3.72 mmol), the reaction mixture was stirred at –91 °C for 45 min.
Product 5e was obtained as a yellow oil (1.21 g, 89%). 1H NMR
(400 MHz, CDCl3): δ = 7.36–7.30 (m, 1 H, Ar), 7.24–7.17 (m, 1 H,
Ar), 7.02–6.90 (m, 2 H, Ar), 5.07–5.01 (m, 1 H, 4-H), 3.89 (s, 3 H,
Ph-OMe), 3.72 (dd, 2JH,H = 11.6 Hz, 3JH,H = 8.6 Hz, 1 H, 5-H),
3.21–3.14 (m, 1 H, 5-H), 2.60–2.47 (m, 1 H, 6-H), 1.13 (d, 3JH,H
= 6.9 Hz, 3 H, 7-H or 8-H), 1.08 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or
8-H) ppm. 31P NMR (162 MHz, CDCl3): δ = –2.02, –2.53 (dr =
19.8:1; 90% de) ppm.
5f: According to General Procedure A, compound 3 (1.03 g,
3.72 mmol) and 3-methoxyphenol (4f, 0.29 mL, 2.60 mmol) were
dissolved in acetone (6.9 mL). After the addition of DBU (0.39 mL,
2.60 mmol), the reaction mixture was stirred at –91 °C for 75 min.
Product 5f was obtained as a yellow oil (0.96 g, quantitative). 1H
NMR (400 MHz, CDCl3): δ = 7.30–7.23 (m, 1 H, Ar), 6.94-6.80
(m, 3 H, Ar), 5.01–4.95 (m, 1 H, 4-H), 3.80 (s, 3 H, Ph-OMe), 3.66
(dd, 2JH,H = 11.6 Hz, 3JH,H = 8.5 Hz, 1 H, 5-H), 3.19–3.11 (m, 1
H, 5-H), 2.56–2.46 (m, 1 H, 6-H), 1.12 (d, 3JH,H = 6.8 Hz, 3 H, 7-
H or 8-H), 1.09 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P
NMR (162 MHz, CDCl3): δ = –1.66, –1.92 (dr = 14.1:1; 87% de)
ppm.
5h: According to General Procedure A, compound 3 (1.03 g,
3.72 mmol) and 2-chlorophenol (4h, 0.33 g, 2.60 mmol) were dis-
solved in acetone (6.9 mL). After the addition of DBU (0.39 mL,
2.60 mmol), the reaction mixture was stirred at –91 °C for 52 min.
Product 5h was obtained as a yellow oil (1.11 g, quantitative). 1H
NMR (400 MHz, CDCl3): δ = 7.51–7.44 (m, 2 H, Ar), 7.33–7.26
(m, 1 H, Ar), 7.24–7.18 (m, 1 H, Ar), 5.11–5.02 (m, 1 H, 4-H),
3.83–3.69 (m, 1 H, 5-H), 3.27–3.17 (m, 1 H, 5-H), 2.59–2.43 (m,
1 H, 6-H), 1.14 (d, 3JH,H = 6.6 Hz, 3 H, 7-H or 8-H), 1.09 (d, 3JH,H
= 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ
= –1.94, –2.83 (dr = 2:1; 34% de) ppm.
5i: According to General Procedure A, compound 3 (1.03 g,
3.72 mmol) and 3-chlorophenol (4i, 0.33 g, 2.60 mmol) were dis-
solved in acetone (6.9 mL). After the addition of DBU (0.39 mL,
2.60 mmol), the reaction mixture was stirred at –91 °C for 60 min.
Product 5i was obtained as a yellow oil (0.80 g, quantitative). 1H
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NMR (400 MHz, CDCl3): δ = 7.34–7.19 (m, 4 H, Ar), 5.01–4.94
(m, 1 H, 4-H), 3.67 (dd, 2JH,H = 11.6 Hz, 3JH,H = 8.5 Hz, 1 H, 5-
H), 3.21–3.14 (m, 1 H, 5-H), 2.53–2.45 (m, 1 H, 6-H), 1.10 (d,
3JH,H = 6.9 Hz, 3 H, 7-H or 8-H), 1.07 (d, 3JH,H = 6.9 Hz, 3 H, 7-
H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ = –1.85 ppm.
5j: According to General Procedure A, compound 3 (1.03 g,
3.72 mmol) and 4-chlorophenol (4j, 0.33 g, 2.60 mmol) were dis-
solved in acetone (6.9 mL). After the addition of DBU (0.39 mL,
2.60 mmol), the reaction mixture was stirred at –91 °C for 52 min.
Product 5j was obtained as a yellow oil (0.93 g, 65%). 1H NMR
(400 MHz, CDCl3): δ = 7.29–7.24 (m, 2 H, Ar), 7.21–7.16 (m, 2 H,
Ar), 4.93–4.85 (m, 1 H, 4-H), 3.57 (dd, 2JH,H = 11.5 Hz, 3JH,H =
4.2 Hz, 1 H, 5-H), 3.14–3.04 (m, 1 H, 5-H), 2.49–2.34 (m, 1 H, 6-
H), 1.04 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H), 1.00 (d, 3JH,H =
6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ =
–1.53, –1.58 (dr = 5.9:1; 70% de) ppm.
5k: According to General Procedure A, compound 3 (1.73 g,
6.20 mmol) and 4-bromophenol (4k, 0.75 g, 4.34 mmol) were dis-
solved in acetone (11.5 mL). After the addition of DBU (0.65 mL,
4.34 mmol), the reaction mixture was stirred at –91 °C for 50 min.
Product 5k was obtained as a yellow oil (0.93 g, 65%). 1H NMR
(400 MHz, CDCl3): δ = 7.55–7.42 (m, 2 H, Ar), 7.23–7.13 (m, 2 H,
Ar), 5.00–4.92 (m, 1 H, 4-H), 3.70–3.61 (m, 1 H, 5-H), 3.33–3.23
(m, 1 H, 5-H), 2.53–2.39 (m, 1 H, 6-H), 0.99 (d, 3JH,H = 6.8 Hz,
3 H, 7-H or 8-H), 0.96 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-H) ppm.
31P NMR (162 MHz, CDCl3): δ = –1.75, –1.81 (dr = 4.5:1; 64%
de) ppm.
5m: According to General Procedure A, compound 3 (1.03 g,
3.72 mmol) and 2-naphthol (4m, 0.54 g, 3.72 mmol) were dissolved
in acetone (6.9 mL). After the addition of DBU (0.56 mL,
3.72 mmol), the reaction mixture was stirred at –91 °C for 45 min.
Product 5m was obtained as a colorless solid (0.93 g, 65%). 1H
NMR (400 MHz, CDCl3): δ = 7.90–7.77 (m, 4 H, Ar), 7.56–7.44
(m, 3 H, Ar), 5.05–5.00 (m, 1 H, 4-H), 3.65 (dd, 2JH,H = 11.6 Hz,
3JH,H = 8.4 Hz, 1 H, 5-H), 3.15 (dd, 2JH,H = 11.5 Hz, 4JH,H =
2.5 Hz, 1 H, 5-H), 2.60–2.50 (m, 1 H, 6-H), 1.14 (d, 3JH,H =
6.8 Hz, 3 H, 7-H or 8-H), 1.11 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-
H) ppm. 31P NMR (162 MHz, CDCl3): δ = –1.46, –1.65 (dr =
26.8:1; 93% de) ppm.
(RP)-11a and (SP)-11a: General Procedure B was applied by using
compound 5a (0.55 g, 1.65 mmol), l-alanine methyl ester hydro-
chloride (9, 0.23 g, 1.65 mmol), and NEt3 (0.69 mL, 4.95 mmol) in
CH2Cl2 (2.4 mL). (RP)-11a: Product (RP)-11a was obtained as a
colorless oil (0.17 g, 25%). 1H NMR (400 MHz, CDCl3): δ = 7.37–
7.28 (m, 4 H, Ar), 7.22–7.16 (m, 1 H, Ar), 5.10 (dd, 2JH,P = 8.9 Hz,
3JH,H = 8.9 Hz, 1 H, NH-Ala), 4.99–4.92 (m, 1 H, 4-H), 4.26–4.13
(m, 1 H, CH-Ala), 3.69–3.62 (m, 1 H, 5-H), 3.65 (s, 3 H, MeO-
Ala), 3.17–3.09 (m, 1 H, 5-H), 2.39–2.27 (m, 1 H, 6-H), 1.43 (d,
3JH,H = 7.0 Hz, 3 H, Me-Ala), 0.98 (d, 3JH,H = 7.1 Hz, 3 H, 7-H
or 8-H), 0.88 (d, 3JH,H = 7.1 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR
(162 MHz, CDCl3): δ = –0.91 ppm. (SP)-11a: Product (SP)-11a was
obtained as a colorless oil (0.03 g, 5%). 1H NMR (400 MHz,
CDCl3): δ = 7.38–7.28 (m, 4 H, Ar), 7.24–7.17 (m, 1 H, Ar), 5.39
(dd, 2JH,P = 8.3 Hz, 3JH,H = 8.3 Hz, 1 H, NH-Ala), 4.64–4.56 (m,
1 H, 4-H), 4.34–4.21 (m, 1 H, CH-Ala), 3.73 (s, 3 H, MeO-Ala),
3.16 (dd, 2JH,H = 11.5 Hz, 3JH,H = 8.5 Hz, 1 H, 5-H), 2.98–2.92
(m, 1 H, 5-H), 2.40–2.27 (m, 1 H, 6-H), 1.38 (d, 3JH,H = 7.0 Hz,
3 H, Me-Ala), 1.00 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-H), 0.97 (d,
3JH,H = 6.8 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz,
CDCl3): δ = 1.36 ppm.
(RP)-11c and (SP)-11c: General Procedure B was applied by using
compound 5c (0.98 g, 2.80 mmol), l-alanine methyl ester hydro-
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chloride (9, 0.39 g, 2.80 mmol), and NEt3 (1.17 mL, 8.40 mmol) in
CH2Cl2 (4.0 mL). (RP)-11c: Product (RP)-11c was obtained as a
colorless oil (0.45 g, 38%). 1H NMR (400 MHz, CDCl3): δ = 7.23–
7.17 (m, 1 H, Ar), 7.13–7.08 (m, 2 H, Ar), 7.01–6.97 (m, 1 H, Ar),
5.10 (dd, 2JH,P = 8.6 Hz, 3JH,H = 8.6 Hz, 1 H, NH-Ala), 4.98–4.92
(m, 1 H, 4-H), 4.24–4.14 (m, 1 H, CH-Ala), 3.68–3.61 (m, 1 H, 5-
H), 3.65 (s, 3 H, MeO-Ala), 3.16–3.10 (m, 1 H, 5-H), 2.39–2.29
(m, 1 H, 6-H), 2.34 (s, 3 H, Ph-Me), 1.42 (d, 3JH,H = 7.1 Hz, 3 H,
Me-Ala), 0.98 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H), 0.90 (d, 3JH,H
= 6.8 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ
= –1.00 ppm. (SP)-11c: Product (SP)-11c was obtained as a color-
less oil (0.05 g, 5%). 1H NMR (400 MHz, CDCl3): δ = 7.24–7.18
(m, 1 H, Ar), 7.13–7.07 (m, 2 H, Ar), 7.02–6.99 (m, 1 H, Ar), 5.37
(dd, 2JH,P = 8.8 Hz, 3JH,H = 8.8 Hz, 1 H, NH-Ala), 4.65–4.56 (m,
1 H, 4-H), 4.33–4.21 (m, 1 H, CH-Ala), 3.72 (s, 3 H, MeO-Ala),
3.18 (dd, 2JH,H = 11.3 Hz, 3JH,H = 8.3 Hz, 1 H, 5-H), 3.01–2.92
(m, 1 H, 5-H), 2.39–2.28 (m, 1 H, 6-H), 2.34 (s, 3 H, Ph-Me), 1.38
(d, 3JH,H = 7.0 Hz, 3 H, Me-Ala), 1.00 (d, 3JH,H = 6.8 Hz, 3 H, 7-
H or 8-H), 0.97 (d, 3JH,H = 7.0 Hz, 3 H, 7-H or 8-H) ppm. 31P
NMR (162 MHz, CDCl3): δ = 1.26 ppm.
(RP)-11e and (SP)-11e: General Procedure B was applied by using
compound 5e (0.85 g, 2.31 mmol), l-alanine methyl ester hydro-
chloride (9, 0.32 g, 2.31 mmol), and NEt3 (0.96 mL, 6.95 mmol) in
CH2Cl2 (3.3 mL). (RP)-11e: Product (RP)-11e was obtained as a
colorless oil (0.28 g, 28%). 1H NMR (400 MHz, CDCl3): δ = 7.34–
7.30 (m, 1 H, Ar), 7.17–7.11 (m, 1 H, Ar), 6.96–6.86 (m, 2 H, Ar),
5.33 (dd, 2JH,P = 8.8 Hz, 3JH,H = 8.8 Hz, 1 H, NH-Ala), 5.06–4.99
(m, 1 H, 4-H), 4.22–4.08 (m, 1 H, CH-Ala), 3.87 (s, 3 H, Ph-OMe),
3.69–3.61 (m, 1 H, 5-H), 3.63 (s, 3 H, MeO-Ala), 3.20–3.14 (m, 1
H, 5-H), 2.64–2.53 (m, 1 H, 6-H), 1.41 (d, 3JH,H = 7.1 Hz, 3 H,
Me-Ala), 1.09 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H), 1.06 (d, 3JH,H
= 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ
= 0.11 ppm. (SP)-11e: Product (SP)-11e was obtained as a colorless
oil (0.015 g, 2%). 1H NMR (400 MHz, CDCl3): δ = 7.35–7.31 (m,
1 H, Ar), 7.18–7.09 (m, 1 H, Ar), 6.98–6.84 (m, 2 H, Ar), 5.32 (dd,
2JH,P = 8.8 Hz, 3JH,H = 8.8 Hz, 1 H, NH-Ala), 4.79–4.73 (m, 1 H,
4-H), 4.33–4.20 (m, 1 H, CH-Ala), 3.87 (s, 3 H, MeO-Ala), 3.72 (s,
3 H, Ph-OMe), 3.45 (dd, 2JH,H = 11.5 Hz, 3JH,H = 8.5 Hz, 1 H, 5-
H), 3.06–3.03 (m, 1 H, 5-H), 2.46–2.36 (m, 1 H, 6-H), 1.34 (d,
3JH,H = 7.1 Hz, 3 H, Me-Ala), 1.03 (d, 3JH,H = 6.9 Hz, 3 H, 7-H
or 8-H), 0.99 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR
(162 MHz, CDCl3): δ = 1.01 ppm.
(RP)-11f and (SP)-11f: General Procedure B was applied by using
compound 5f (0.80 g, 2.20 mmol), l-alanine methyl ester hydro-
chloride (9, 0.31 g, 2.20 mmol), and NEt3 (0.92 mL, 6.60 mmol)
in CH2Cl2 (3.1 mL). (RP)-11f: Product (RP)-11f was obtained as a
colorless oil (0.36 g, 38%). 1H NMR (400 MHz, CDCl3): δ = 7.23–
7.14 (m, 1 H, Ar), 6.91–6.83 (m, 2 H, Ar), 6.75–6.67 (m, 1 H, Ar),
5.09 (dd, 2JH,P = 7.5 Hz, 3JH,H = 7.5 Hz, 1 H, NH-Ala), 4.97–4.89
(m, 1 H, 4-H), 4.24–4.12 (m, 1 H, CH-Ala), 3.76 (s, 3 H, Ph-OMe),
3.67–3.59 (m, 1 H, 5-H), 3.63 (s, 3 H, MeO-Ala), 3.15–3.07 (m, 1
H, 5-H), 2.39–2.27 (m, 1 H, 6-H), 1.39 (d, 3JH,H = 7.0 Hz, 3 H,
Me-Ala), 0.96 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-H), 0.87 (d, 3JH,H
= 6.7 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ
= –0.99 ppm. (SP)-11f: Product (SP)-11f was obtained as a colorless
oil (0.05 g, 5%). 1H NMR (400 MHz, CDCl3): δ = 7.25–7.20 (m, 1
H, Ar), 6.93–6.85 (m, 2 H, Ar), 6.79–6.74 (m, 1 H, Ar), 5.40 (dd,
2JH,P = 8.8 Hz, 3JH,H = 8.8 Hz, 1 H, NH-Ala), 4.63–4.57 (m, 1 H,
4-H), 4.33–4.22 (m, 1 H, CH-Ala), 3.79 (s, 3 H, Ph-OMe), 3.72 (s,
3 H, MeO-Ala), 3.18 (dd, 2JH,H = 11.5 Hz, 3JH,H = 8.5 Hz, 1 H, 5-
H), 2.99–2.93 (m, 1 H, 5-H), 2.39–2.27 (m, 1 H, 6-H), 1.39 (d,
3JH,H = 7.1 Hz, 3 H, Me-Ala), 0.99 (d, 3JH,H = 6.9 Hz, 3 H, 7-H
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or 8-H), 0.96 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR
(162 MHz, CDCl3): δ = 1.31 ppm.
(RP)-11h and (SP)-11h: General Procedure B was applied by using
compound 5h (1.04 g, 2.80 mmol), l-alanine methyl ester hydro-
chloride (9, 0.39 g, 2.80 mmol), and NEt3 (1.17 mL, 8.40 mmol) in
CH2Cl2 (4.0 mL). (RP)-11h: Product (RP)-11h was obtained as a
colorless oil (0.16 g, 13%). 1H NMR (400 MHz, CDCl3): δ = 7.57–
7.53 (m, 1 H, Ar), 7.43–7.39 (m, 1 H, Ar), 7.26–7.21 (m, 1 H, Ar),
7.14–7.09 (m, 1 H, Ar), 5.36 (dd, 2JH,P = 8.3 Hz, 3JH,H = 8.3 Hz,
1 H, NH-Ala), 5.07–5.01 (m, 1 H, 4-H), 4.26–4.18 (m, 1 H, CH-
Ala), 3.68 (dd, 2JH,H = 11.6 Hz, 3JH,H = 9.3 Hz, 1 H, 5-H), 3.66 (s,
3 H, MeO-Ala), 3.23–3.17 (m, 1 H, 5-H), 2.64–2.54 (m, 1 H, 6-
H), 1.44 (d, 3JH,H = 7.2 Hz, 3 H, Me-Ala), 1.12 (d, 3JH,H = 6.9 Hz,
3 H, 7-H or 8-H), 1.05 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H) ppm.
31P NMR (162 MHz, CDCl3): δ = –0.38 ppm. (SP)-11h: Product
(SP)-11h was obtained as a colorless oil (0.10 g, 8%). 1H NMR
(400 MHz, CDCl3): δ = 7.45–7.41 (m, 2 H, Ar), 7.25–7.21 (m, 1 H,
Ar), 7.16–7.10 (m, 1 H, Ar), 5.37 (dd, 2JH,P = 8.3 Hz, 3JH,H =
8.3 Hz, 1 H, NH-Ala), 4.86–4.80 (m, 1 H, 4-H), 4.32–4.23 (m, 1
H, CH-Ala), 3.72 (s, 3 H, MeO-Ala), 3.59 (dd, 2JH,H = 11.6 Hz,
3JH,H = 8.6 Hz, 1 H, 5-H), 3.13–3.08 (m, 1 H, 5-H), 2.46–2.36 (m,
1 H, 6-H), 1.39 (d, 3JH,H = 7.0 Hz, 3 H, Me-Ala), 1.05 (d, 3JH,H =
6.9 Hz, 3 H, 7-H or 8-H), 1.01 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-
H) ppm. 31P NMR (162 MHz, CDCl3): δ = 0.77 ppm.
(RP)-11i and (SP)-11i: General Procedure B was applied by using
compound 5i (0.61 g, 1.65 mmol), l-alanine methyl ester hydro-
chloride (9, 0.23 g, 1.65 mmol), and NEt3 (0.68 mL, 4.94 mmol)
in CH2Cl2 (2.3 mL). (RP)-11i: Product (RP)-11i was obtained as a
colorless oil (0.13 g, 18%). 1H NMR (400 MHz, CDCl3): δ = 7.36–
7.31 (m, 1 H, Ar), 7.29–7.15 (m, 3 H, Ar), 5.12 (dd, 2JH,P = 8.6 Hz,
3JH,H = 8.6 Hz, 1 H, NH-Ala), 4.98–4.91 (m, 1 H, 4-H), 4.24–4.11
(m, 1 H, CH-Ala), 3.70–3.62 (m, 1 H, 5-H), 3.66 (s, 3 H, MeO-
Ala), 3.17–3.11 (m, 1 H, 5-H), 2.40–2.28 (m, 1 H, 6-H), 1.42 (d,
3JH,H = 7.3 Hz, 3 H, Me-Ala), 0.99 (d, 3JH,H = 6.8 Hz, 3 H, 7-H
or 8-H), 0.91 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR
(162 MHz, CDCl3): δ = –0.64 ppm. (SP)-11i: Product (SP)-11i was
obtained as a colorless oil (0.05 g, 7%). 1H NMR (400 MHz,
CDCl3): δ = 7.35–7.31 (m, 1 H, Ar), 7.31–7.27 (m, 1 H, Ar), 7.22–
7.17 (m, 2 H, Ar), 5.38 (dd, 2JH,P = 8.6 Hz, 3JH,H = 8.6 Hz, 1 H,
NH-Ala), 4.69–4.61 (m, 1 H, 4-H), 4.33–4.19 (m, 1 H, CH-Ala),
3.73 (s, 3 H, MeO-Ala), 3.29 (dd, 2JH,H = 11.7 Hz, 3JH,H = 8.6 Hz,
1 H, 5-H), 3.05–2.98 (m, 1 H, 5-H), 2.40–2.27 (m, 1 H, 6-H), 1.37
(d, 3JH,H = 7.0 Hz, 3 H, Me-Ala), 1.01 (d, 3JH,H = 7.1 Hz, 3 H, 7-
H or 8-H), 0.98 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-H) ppm. 31P
NMR (162 MHz, CDCl3): δ = 1.34 ppm.
(RP)-11j and (SP)-11j: General Procedure B was applied by using
compound 5j (0.78 g, 2.12 mmol), l-alanine methyl ester hydro-
chloride (9, 0.30 g, 2.12 mmol), and NEt3 (0.89 mL, 6.36 mmol)
in CH2Cl2 (3.0 mL). (RP)-11j: Product (RP)-11j was obtained as a
colorless oil (0.21 g, 23%). 1H NMR (400 MHz, CDCl3): δ = 7.30–
7.16 (m, 4 H, Ar), 5.12 (dd, 2JH,P = 8.4 Hz, 3JH,H = 8.4 Hz, 1 H,
NH-Ala), 4.92–4.85 (m, 1 H, 4-H), 4.16–4.07 (m, 1 H, CH-Ala),
3.63–3.57 (m, 1 H, 5-H), 3.60 (s, 3 H, MeO-Ala), 3.17–3.09 (m, 1
H, 5-H), 2.33–2.20 (m, 1 H, 6-H), 1.42 (d, 3JH,H = 7.3 Hz, 3 H,
Me-Ala), 0.99 (d, 3JH,H = 7.1 Hz, 3 H, 7-H or 8-H), 0.89 (d, 3JH,H
= 6.8 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ
= –0.58 ppm. (SP)-11j: Product (SP)-11j was obtained as a colorless
oil (0.11 g, 6%). 1H NMR (400 MHz, CDCl3): δ = 7.35–7.20 (m, 4
H, Ar), 5.39 (dd, 2JH,P = 8.6 Hz, 3JH,H = 8.6 Hz, 1 H, NH-Ala),
4.67–4.56 (m, 1 H, 4-H), 4.32–4.18 (m, 1 H, CH-Ala), 3.73 (s, 3 H,
MeO-Ala), 3.25 (dd, 2JH,H = 11.4 Hz, 3JH,H = 8.3 Hz, 1 H, 5-H),
3.04–2.94 (m, 1 H, 5-H), 2.39–2.26 (m, 1 H, 6-H), 1.38 (d, 3JH,H
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= 7.3 Hz, 3 H, Me-Ala), 0.99 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-
H), 0.97 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR
(162 MHz, CDCl3): δ = 1.43 ppm.
(RP)-11k and (SP)-11k: General Procedure B was applied by using
compound 5k (1.47 g, 3.56 mmol), l-alanine methyl ester hydro-
chloride (9, 0.50 g, 3.56 mmol), and NEt3 (1.50 mL, 10.68 mmol)
in CH2Cl2 (5.1 mL). (RP)-11k: Product (RP)-11k was obtained as a
colorless oil (0.29 g, 17%). 1H NMR (400 MHz, CDCl3): δ = 7.46–
7.41 (m, 2 H, Ar), 7.21–7.17 (m, 2 H, Ar), 5.11 (dd, 2JH,P = 8.5 Hz,
3JH,H = 8.5 Hz, 1 H, NH-Ala), 4.96–4.91 (m, 1 H, 4-H), 4.22–4.12
(m, 1 H, CH-Ala), 3.68–3.63 (m, 1 H, 5-H), 3.66 (s, 3 H, MeO-
Ala), 3.15–3.12 (m, 1 H, 5-H), 2.36–2.27 (m, 1 H, 6-H), 1.41 (d,
3JH,H = 7.3 Hz, 3 H, Me-Ala), 0.98 (d, 3JH,H = 7.0 Hz, 3 H, 7-H
or 8-H), 0.89 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR
(162 MHz, CDCl3): δ = –0.66 ppm. (SP)-11k: Product (SP)-11k was
obtained as a colorless oil (0.07 g, 4%). 1H NMR (400 MHz,
CDCl3): δ = 7.49–7.43 (m, 2 H, Ar), 7.22–7.17 (m, 2 H, Ar), 5.39
(dd, 2JH,P = 8.6 Hz, 3JH,H = 8.6 Hz, 1 H, NH-Ala), 4.63–4.58 (m,
1 H, 4-H), 4.32–4.20 (m, 1 H, CH-Ala), 3.73 (s, 3 H, MeO-Ala),
3.24 (dd, 2JH,H = 11.4 Hz, 3JH,H = 8.4 Hz, 1 H, 5-H), 3.01–2.98
(m, 1 H, 5-H), 2.38–2.27 (m, 1 H, 6-H), 1.38 (d, 3JH,H = 6.8 Hz,
3 H, Me-Ala), 0.99 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H), 0.97 (d,
3JH,H = 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz,
CDCl3): δ = 1.33 ppm.
(RP)-11m and (SP)-11m: General Procedure B was applied by using
compound 5m (0.77 g, 1.99 mmol), l-alanine methyl ester hydro-
chloride (9, 0.28 g, 1.99 mmol), and NEt3 (0.83 mL, 5.97 mmol) in
CH2Cl2 (2.8 mL). (RP)-11m: Product (RP)-11m was obtained as a
colorless oil (0.28 g, 30%). 1H NMR (400 MHz, CDCl3): δ = 7.84–
7.75 (m, 4 H, Ar), 7.51–7.42 (m, 3 H, Ar), 5.17 (dd, 2JH,P = 8.5 Hz,
3JH,H = 8.5 Hz, 1 H, NH-Ala), 5.02–4.96 (m, 1 H, 4-H), 4.26–4.15
(m, 1 H, CH-Ala), 3.67 (dd, 2JH,H = 11.3 Hz, 3JH,H = 9.3 Hz, 1 H,
5-H), 3.52 (s, 3 H, MeO-Ala), 3.16–3.13 (m, 1 H, 5-H), 2.44–2.34
(m, 1 H, 6-H), 1.43 (d, 3JH,H = 7.0 Hz, 3 H, Me-Ala), 0.98 (d, 3JH,H
= 7.0 Hz, 3 H, 7-H or 8-H), 0.85 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or
8-H) ppm. 31P NMR (162 MHz, CDCl3): δ = –0.60 ppm. (SP)-11m:
Product (SP)-11m was obtained as a colorless solid (0.05 g, 6%).
1H NMR (400 MHz, CDCl3): δ = 7.86–7.74 (m, 4 H, Ar), 7.53–
7.44 (m, 3 H, Ar), 5.46 (dd, 2JH,P = 8.8 Hz, 3JH,H = 8.8 Hz, 1 H,
NH-Ala), 4.65–4.60 (m, 1 H, 4-H), 4.37–4.25 (m, 1 H, CH-Ala),
3.73 (s, 3 H, MeO-Ala), 3.07 (dd, 2JH,H = 11.3 Hz, 3JH,H = 8.3 Hz,
1 H, 5-H), 2.93–2.90 (m, 1 H, 5-H), 2.40–2.30 (m, 1 H, 6-H), 1.38
(d, 3JH,H = 7.0 Hz, 3 H, Me-Ala), 0.99 (d, 3JH,H = 6.9 Hz, 3 H, 7-
H or 8-H), 0.97 (d, 3JH,H = 6.9 Hz, 3 H, 7-H or 8-H) ppm. 31P
NMR (162 MHz, CDCl3): δ = 1.52 ppm.
(RP)-12b and (SP)-12b: General Procedure B was applied by using
compound 5b (0.52 g, 1.49 mmol), l-alanine benzyl ester hydro-
chloride (10, 0.32 g, 1.49 mmol), and NEt3 (0.62 mL, 4.5 mmol) in
CH2Cl2 (2.1 mL). (RP)-12b: Product (RP)-12b was obtained as a
colorless oil (0.40 g, 55%). 1H NMR (400 MHz, CDCl3): δ = 7.37–
7.27 (m, 6 H, Ar), 7.19–7.02 (m, 3 H, Ar), 5.27 (dd, 2JH,P = 8.5 Hz,
3JH,H = 8.5 Hz, 1 H, NH-Ala), 5.14–4.99 (m, 3 H, 4-H, CH2-Bn),
4.31–4.16 (m, 1 H, CH-Ala), 3.66 (dd, 2JH,H = 11.3 Hz, 3JH,H =
9.5 Hz, 1 H, 5-H), 3.21–3.14 (m, 1 H, 5-H), 2.57–2.46 (m, 1 H, 6-
H), 2.34 (s, 3 H, Ph-Me), 1.44 (d, 3JH,H = 7.3 Hz, 3 H, Me-Ala),
1.08 (d, 3JH,H = 7.0 Hz, 3 H, 7-H or 8-H), 1.04 (d, 3JH,H = 7.0 Hz,
3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ =
–0.95 ppm. (SP)-12b: Product (SP)-12b was obtained as a colorless
oil (0.12 g, 16%). 1H NMR (400 MHz, CDCl3): δ = 7.38–7.31 (m,
5 H, Ar), 7.22–7.03 (m, 4 H, Ar), 5.45 (dd, 2JH,P = 8.6 Hz, 3JH,H
= 8.6 Hz, 1 H, NH-Ala), 5.16 (s, 2 H, CH2-Bn), 4.79–4.72 (m, 1
H, 4-H), 4.39–4.28 (m, 1 H, CH-Ala), 3.46 (dd, 2JH,H = 11.6 Hz,
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3JH,H = 8.4 Hz, 1 H, 5-H), 3.06–3.00 (m, 1 H, 5-H), 2.37–2.33 (m,
1 H, 6-H), 2.35 (s, 3 H, Ph-Me), 1.40 (d, 3JH,H = 7.3 Hz, 3 H, Me-
Ala), 0.96 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-H), 0.95 (d, 3JH,H =
6.8 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ =
0.65 ppm.
(RP)-12d and (SP)-12d: General Procedure B was applied by using
compound 5d (0.72 g, 2.0 mmol), l-alanine benzyl ester hydrochlo-
ride (10, 0.44 g, 2.0 mmol), and NEt3 (0.85 mL, 6.1 mmol) in
CH2Cl2 (2.9 mL). (RP)-12d: Product (RP)-12d was obtained as a
colorless oil (0.70 g, 70%). 1H NMR (400 MHz, CDCl3): δ = 7.38–
7.31 (m, 3 H, Ar), 7.31–7.27 (m, 2 H, Ar), 7.20–7.14 (m, 2 H, Ar),
7.11–7.04 (m, 2 H, Ar), 5.17–5.07 (m, 3 H, NH-Ala, CH2-Bn),
4.98–4.89 (m, 1 H, 4-H), 4.31–4.15 (m, 1 H, CH-Ala), 3.63 (dd,
2JH,H = 11.6 Hz, 3JH,H = 9.6 Hz, 1 H, 5-H), 3.14–3.08 (m, 1 H, 5-
H), 2.39–2.32 (m, 1 H, 6-H), 2.30 (s, 3 H, Ph-Me), 1.44 (d, 3JH,H
= 7.4 Hz, 3 H, Me-Ala), 0.98 (d, 3JH,H = 7.0 Hz, 3 H, 7-H or 8-
H), 0.88 (d, 3JH,H = 6.8 Hz, 3 H, 7-H or 8-H) ppm. 31P NMR
(162 MHz, CDCl3): δ = –0.84 ppm. (SP)-12d: Product (SP)-12d was
obtained as a colorless oil (0.055 g, 5%). 1H NMR (400 MHz,
CDCl3): δ = 7.32–7.24 (m, 5 H, Ar), 7.14–7.09 (m, 2 H, Ar), 7.08–
7.02 (m, 2 H, Ar), 5.34 (dd, 2JH,P = 8.3 Hz, 3JH,H = 8.3 Hz, 1 H,
NH-Ala), 5.09 (s, 2 H, CH2-Bn), 4.54–4.46 (m, 1 H, 4-H), 4.31–
4.19 (m, 1 H, CH-Ala), 3.08 (dd, 2JH,H = 11.4 Hz, 3JH,H = 8.3 Hz,
1 H, 5-H), 2.89–2.83 (m, 1 H, 5-H), 2.25 (s, 3 H, Ph-Me), 2.24–
2.15 (m, 1 H, 6-H), 1.32 (d, 3JH,H = 7.1 Hz, 3 H, Me-Ala), 0.85 (d,
3JH,H = 6.8 Hz, 3 H, 7-H or 8-H), 0.83 (d, 3JH,H = 7.0 Hz, 3 H, 7-
H or 8-H) ppm. 31P NMR (162 MHz, CDCl3): δ = 1.44 ppm.
(SP)-16j: General Procedure C was applied by using compound
(RP)-11j (0.21 g, 0.47 mmol), d4T (15, 0.16 g, 0.70 mmol), tert-but-
ylmagnesium chloride (0.83 mL, 1.41 mmol), and THF/CH3CN
(6.2 mL). Product (SP)-16j was obtained as a colorless foam
(0.047 g, 20%). 1H NMR (400 MHz, CDCl3): δ = 8.19 (br. s, 1 H,
NH), 7.32–7.27 (m, 3 H, Ar), 7.15–7.09 (m, 2 H, Ar, 6-H), 7.04–
6.99 (m, 1 H, 1-H), 6.38–6.32 (m, 1 H, 2-H), 5.93–5.87 (m, 1 H,
3-H), 5.08–5.00 (m, 1 H, 4-H), 4.41–4.27 (m, 2 H, 5-H), 4.01–
3.88 (m, 1 H, CH-Ala), 3.71 (s, 3 H, MeO-Ala), 3.59 (dd, 2JH,P =
10.5 Hz, 3JH,H = 10.5 Hz, 1 H, NH-Ala), 1.82 (s, 3 H, Me-Th),
1.32 (d, 3JH,H = 7.0 Hz, 3 H, Me-Ala) ppm. 31P NMR (162 MHz,
CDCl3): δ = 3.13, 2.59 (dr = 37:1; 95% de) ppm.
(RP)-16j: General Procedure C was applied by using compound
(SP)-11j (0.05 g, 0.10 mmol), d4T (15, 0.04 g, 0.16 mmol), tert-but-
ylmagnesium chloride (0.18 mL, 0.31 mmol), and THF/CH3CN
(1.4 mL). Product (RP)-16j was obtained as a colorless foam
(0.014 g, 26%). 1H NMR (400 MHz, CDCl3): δ = 8.49 (br. s, 1 H,
NH), 7.32–7.27 (m, 2 H, Ar), 7.23–7.19 (m, 1 H, 6-H), 7.18–7.12
(m, 2 H, Ar), 7.04–6.98 (m, 1 H, 1-H), 6.32–6.26 (m, 1 H, 2-H),
5.96–5.87 (m, 1 H, 3-H), 5.06–4.95 (m, 1 H, 4-H), 4.34–4.20 (m,
2 H, 5-H), 4.03–3.91 (m, 1 H, CH-Ala), 3.75–3.67 (m, 1 H, NH-
Ala), 3.71 (s, 3 H, MeO-Ala), 1.87 (d, 4JH,H = 1.4 Hz, 3 H, Me-
Th), 1.36 (d, 3JH,H = 7.0 Hz, 3 H, Me-Ala) ppm. 31P NMR
(162 MHz, CDCl3): δ = 2.62 ppm.
(SP)-16k: General Procedure C was applied by using compound
(RP)-11k (0.15 g, 0.32 mmol), d4T (15, 0.11 g, 0.48 mmol), tert-but-
ylmagnesium chloride (0.56 mL, 0.96 mmol), and THF/CH3CN
(4.3 mL). Product (SP)-16k was obtained as a colorless foam
(0.026 g, 15%). 1H NMR (400 MHz, CDCl3): δ = 8.52 (br. s, 1 H,
NH), 7.43 (d, 3JH,H = 8.8 Hz, 2 H, Ar), 7.29–7-27 (m, 1 H, 6-H),
7.07 (d, 3JH,H = 8.5 Hz, 2 H, Ar), 6.37–6.32 (m, 1 H, 2-H), 5.92–
5.86 (m, 1 H, 3-H), 5.07–5.00 (m, 1 H, 4-H), 4.40–4.27 (m, 2 H,
5-H), 4.03–3.90 (m, 1 H, CH-Ala), 3.77–3.64 (m, 1 H, NH-Ala),
3.71 (s, 3 H, MeO-Ala), 1.82 (s, 3 H, Me-Th), 1.32 (d, 3JH,H =
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7.1 Hz, 3 H, Me-Ala) ppm. 31P NMR (162 MHz, CDCl3): δ = 3.13,
2.54 (dr = 27:1; 93% de) ppm.
(RP)-16k: General Procedure C was applied by using compound
(SP)-11k (0.13 g, 0.26 mmol), d4T (15, 0.09 g, 0.39 mmol), tert-but-
ylmagnesium chloride (0.46 mL, 0.79 mmol), and THF/CH3CN
(3.5 mL). Product (RP)-16k was obtained as a colorless foam
(0.074 g, 50%). 1H NMR (400 MHz, CDCl3): δ = 8.83 (br. s, 1 H,
NH), 7.46–7.40 (m, 2 H, Ar), 7.21 (d, 4JH,H = 1.0 Hz, 1 H, 6-H),
7.12–7.06 (m, 2 H, Ar), 7.02–6.98 (m, 1 H, 1-H), 6.32–6.24 (m, 1
H, 2-H), 5.94–5.87 (m, 1 H, 3-H), 5.03–4.96 (m, 1 H, 4-H), 4.33–
4.19 (m, 2 H, 5-H), 4.03–3.91 (m, 1 H, CH-Ala), 3.80 (dd, 2JH,P
= 11.3 Hz, 3JH,H = 9.5 Hz, 1 H, NH-Ala), 3.71 (s, 3 H, MeO-Ala),
1.86 (s, 4JH,H = 1.0 Hz, 3 H, Me-Th), 1.36 (d, 3JH,H = 7.0 Hz, 3 H,
Me-Ala) ppm. 31P NMR (162 MHz, CDCl3): δ = 2.58 ppm.
(SP)-17b: General Procedure C was applied by using compound
(RP)-12b (0.22 g, 0.44 mmol), d4T (15, 0.15 g, 0.66 mmol), tert-but-
ylmagnesium chloride (0.78 mL, 1.32 mmol), and THF/CH3CN
(5.9 mL). Product (SP)-17b was obtained as a colorless foam
(0.027 g, 11%). 1H NMR (400 MHz, CDCl3): δ = 8.32 (br. s, 1 H,
NH), 7.39–7.28 (m, 6 H, Ar, 6-H), 7.24–6.98 (m, 5 H, Ar, 1-H),
6.37–6.28 (m, 1 H, 2-H), 5.93–5.83 (m, 1 H, 3-H), 5.17 (d, 2JH,H
= 12.1 Hz, 1 H, CH2-Bn), 5.12 (d, 2JH,H = 12.1 Hz, 1 H, CH2-Bn),
5.03–4.94 (m, 1 H, 4-H), 4.39–4.18 (m, 2 H, 5-H), 4.13–3.99 (m,
1 H, CH-Ala), 3.58 (dd, 2JH,P = 10.1 Hz, 3JH,H = 10.1 Hz, 1 H,
NH-Ala), 2.24 (s, 3 H, Me-Ph), 1.75 (s, 3 H, Me-Th), 1.35 (d, 3JH,H
= 6.8 Hz, 3 H, Me-Ala) ppm. 31P NMR (162 MHz, CDCl3): δ =
2.95 ppm.
(RP)-17b: General Procedure C was applied by using compound
(SP)-12b (0.07 g, 0.14 mmol), d4T (15, 0.05 g, 0.22 mmol), tert-but-
ylmagnesium chloride (0.26 mL, 0.45 mmol), and THF/CH3CN
(1.9 mL). Product (RP)-17b was obtained as a colorless foam
(0.018 g, 22%). 1H NMR (400 MHz, CDCl3): δ = 8.46 (br. s, 1 H,
NH), 7.39–7.27 (m, 6 H, Ar), 7.22–7.19 (m, 1 H, 6-H), 7.18–7.02
(m, 4 H, Ar), 6.99–6.95 (m, 1 H, 1-H), 6.23–6.17 (m, 1 H, 2-H),
5.88–5.81 (m, 1 H, 3-H), 5.10 (d, 2JH,H = 12.3 Hz, 1 H, CH2-Bn),
5.05 (d, 2JH,H = 12.3 Hz, 1 H, CH2-Bn), 4.94–4.88 (m, 1 H, 4-H),
4.24–4.18 (m, 2 H, 5-H), 4.10–3.98 (m, 1 H, CH-Ala), 3.72 (dd,
2JH,P = 10.4 Hz, 3JH,H = 10.4 Hz, 1 H, NH-Ala), 2.26 (s, 3 H, Me-
Ph), 1.83 (s, 3 H, Me-Th), 1.39 (d, 3JH,H = 6.9 Hz, 3 H, Me-Ala)
ppm. 31P NMR (162 MHz, CDCl3): δ = 2.62 ppm.
(SP)-17d: General Procedure C was applied by using compound
(RP)-12d (0.16 g, 0.33 mmol), d4T (15, 0.11 g, 0.49 mmol), tert-but-
ylmagnesium chloride (0.57 mL, 0.98 mmol), and THF/CH3CN
(4.4 mL). Product (SP)-17d was obtained as a colorless foam
(0.025 g, 14%). 1H NMR (400 MHz, CDCl3): δ = 8.49 (br. s, 1 H,
NH), 7.38–7.28 (m, 6 H, Ar, 6-H), 7.10–6.98 (m, 5 H, Ar, 1-H),
6.33–6.29 (m, 1 H, 2-H), 5.87–5.82 (m, 1 H, 3-H), 5.14 (d, 2JH,H
= 12.3 Hz, 1 H, CH2-Bn), 5.10 (d, 2JH,H = 12.5 Hz, 1 H, CH2-Bn),
4.99–4.94 (m, 1 H, 4-H), 4.36–4.21 (m, 2 H, 5-H), 4.08–3.96 (m,
1 H, CH-Ala), 3.60 (dd, 2JH,P = 10.8 Hz, 3JH,H = 10.8 Hz, 1 H,
NH-Ala), 2.29 (s, 3 H, Me-Ph), 1.79 (s, 3 H, Me-Th), 1.32 (d, 3JH,H
= 7.1 Hz, 3 H, Me-Ala) ppm. 31P NMR (162 MHz, CDCl3): δ =
3.18, 2.26 (dr = 33:1; 94% de) ppm.
(RP)-17d: General Procedure C was applied by using compound
(SP)-12d (0.11 g, 0.24 mmol), d4T (15, 0.08 g, 0.35 mmol), tert-but-
ylmagnesium chloride (0.41 mL, 0.70 mmol), and THF/CH3CN
(3.1 mL). Product (RP)-17d was obtained as a colorless foam
(0.058 g, 44%). 1H NMR (400 MHz, CDCl3): δ = 8.01 (br. s, 1 H,
NH), 7.40–7.29 (m, 5 H, Ar), 7.25–7.22 (m, 1 H, 6-H), 7.12–7.02
(m, 4 H, Ar), 7.00–6.95 (m, 1 H, 1-H), 6.22–6.17 (m, 1 H, 2-H),
5.88–5.82 (m, 1 H, 3-H), 5.15 (d, 2JH,H = 12.3 Hz, 1 H, CH2-Bn),
5.13 (d, 2JH,H = 12.3 Hz, 1 H, CH2-Bn), 4.97–4.90 (m, 1 H, 4-H),
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4.29–4.15 (m, 2 H, 5-H), 4.07–3.95 (m, 1 H, CH-Ala), 3.56 (dd,
2JH,P = 11.1 Hz, 3JH,H = 9.7 Hz, 1 H, NH-Ala), 2.30 (s, 3 H, Me-
Ph), 1.84 (s, 4JH,H = 1.0 Hz, 3 H, Me-Th), 1.36 (d, 3JH,H = 7.1 Hz,
3 H, Me-Ala) ppm. 31P NMR (162 MHz, CDCl3): δ = 2.62 ppm.
Antiretroviral Evaluation: Human immunodeficiency virus type 1
(HIV-1) was originally obtained from a persistently HIV-infected
H9 cell line, as described previously, and was kindly provided by
Dr. R. C. Gallo (then at the National Institutes of Health, Be-
thesda, MD). Virus stocks were prepared from the supernatants of
HIV-1-infected MT-4 cells. HIV-2 (strain ROD) was kindly pro-
vided by Dr. L. Montagnier (then at the Pasteur Institute, Paris,
France), and virus stocks were prepared from the supernatants of
HIV-2-infected MT-4 cells. CEM cells were obtained from the
American Tissue Culture Collection (Rockville, MD). CEM cells
were infected with HIV as described previously.[18] Briefly,
4105 CEM cells/mL were infected with HIV-1(IIIB) or HIV-
2(ROD) at approximately 100 CCID50 (50% cell culture infective
dose) per mL of cell suspension. The thymidine kinase deficient
CEM cell cultures were also infected with HIV-2(ROD). Then, the
infected cell suspensions (100 μL) were transferred into 96-well
microtiter plate wells and mixed with the appropriate dilutions of
the test compounds (100 μL). After 4–5 d, giant cell formation was
recorded microscopically in the HIV-infected cell cultures. The 50%
effective concentration was defined as the compound concentration
required to inhibit virus-induced cytopathicity by 50%. The 50%
cytostatic concentration was defined as the compound concentra-
tion required to block CEM cell proliferation by 50%, as derived
by counting the cell numbers from CEM cell cultures exposed to
different compound concentrations by using a Coulter Particle
Counter ZI (Analysis, Gent, Belgium).
Supporting Information (see footnote on the first page of this arti-
cle): 13C NMR spectroscopic data; mass spectrometric data; analyt-
ical HPLC data of phosphoramidate prodrugs 16j,k and 17b,d.
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